163 related articles for article (PubMed ID: 37615760)
1. The value of baseline 18F-sodium fluoride and 18F-choline PET activity for identifying responders to radium-223 treatment in castration-resistant prostate cancer bone metastases.
Donners R; Tunariu N; Tovey H; Hall E; Chua S; Cook G; Du Y; Blackledge MD; Parker CC; Koh DM
Eur Radiol; 2024 Feb; 34(2):1146-1154. PubMed ID: 37615760
[TBL] [Abstract][Full Text] [Related]
2. Uptake of Radium-223 Dichloride and Early [
Letellier A; Johnson AC; Kit NH; Savigny JF; Batalla A; Parienti JJ; Aide N
Mol Imaging Biol; 2018 Jun; 20(3):482-491. PubMed ID: 29027074
[TBL] [Abstract][Full Text] [Related]
3. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
4. Quantitative Assessment of Early [
Harmon SA; Perk T; Lin C; Eickhoff J; Choyke PL; Dahut WL; Apolo AB; Humm JL; Larson SM; Morris MJ; Liu G; Jeraj R
J Clin Oncol; 2017 Aug; 35(24):2829-2837. PubMed ID: 28654366
[TBL] [Abstract][Full Text] [Related]
5. Whole-Body [
Muzi M; O'Sullivan F; Perk TG; Muzi JP; Mankoff DA; Jeraj R; Duan F; Yu EY
Tomography; 2021 Apr; 7(2):139-153. PubMed ID: 33923126
[TBL] [Abstract][Full Text] [Related]
6. Impact of Anatomic Location of Bone Metastases on Prognosis in Metastatic Castration-Resistant Prostate Cancer.
Roth AR; Harmon SA; Perk TG; Eickhoff J; Choyke PL; Kurdziel KA; Dahut WL; Apolo AB; Morris MJ; Perlman SB; Liu G; Jeraj R
Clin Genitourin Cancer; 2019 Aug; 17(4):306-314. PubMed ID: 31221545
[TBL] [Abstract][Full Text] [Related]
7. Repeatability of Quantitative 18F-NaF PET: A Multicenter Study.
Lin C; Bradshaw T; Perk T; Harmon S; Eickhoff J; Jallow N; Choyke PL; Dahut WL; Larson S; Humm JL; Perlman S; Apolo AB; Morris MJ; Liu G; Jeraj R
J Nucl Med; 2016 Dec; 57(12):1872-1879. PubMed ID: 27445292
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of bone metastases by 18F-choline PET/CT in a patient with castration-resistant prostate cancer treated with radium-223.
Scalzi P; Baiocco C; Genovese S; Trevisan A; Sirotova Z; Poti C
Urologia; 2017 Feb; 84(1):61-64. PubMed ID: 27911459
[TBL] [Abstract][Full Text] [Related]
9. Comparison of [
Uprimny C; Svirydenka A; Fritz J; Kroiss AS; Nilica B; Decristoforo C; Haubner R; von Guggenberg E; Buxbaum S; Horninger W; Virgolini IJ
Eur J Nucl Med Mol Imaging; 2018 Oct; 45(11):1873-1883. PubMed ID: 29766246
[TBL] [Abstract][Full Text] [Related]
10. The Relationship Between Total Lesion Activity on
Filippi L; Basile P; Schillaci O; Bagni O
Cancer Biother Radiopharm; 2020 Aug; 35(6):398-403. PubMed ID: 32109140
[TBL] [Abstract][Full Text] [Related]
11. Prediction of therapy response in bone-predominant metastatic breast cancer: comparison of [
Azad GK; Taylor BP; Green A; Sandri I; Swampillai A; Harries M; Kristeleit H; Mansi J; Goh V; Cook GJR
Eur J Nucl Med Mol Imaging; 2019 Apr; 46(4):821-830. PubMed ID: 30506455
[TBL] [Abstract][Full Text] [Related]
12. Baseline
García Vicente AM; González García B; Amo-Salas M; García Carbonero I; Cassinello Espinosa J; Gómez-Aldaraví Gutierrez JL; Suarez Hinojosa L; Soriano Castrejón Á
Clin Transl Oncol; 2019 Mar; 21(3):289-297. PubMed ID: 30006674
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of 18F-choline PET/CT metabolic parameters in patients with metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide.
Caroli P; De Giorgi U; Scarpi E; Fantini L; Moretti A; Galassi R; Celli M; Conteduca V; Rossi L; Bianchi E; Paganelli G; Matteucci F
Eur J Nucl Med Mol Imaging; 2018 Mar; 45(3):348-354. PubMed ID: 29110067
[TBL] [Abstract][Full Text] [Related]
14. Prognostic Factors in Patients Treated with 223Ra: The Role of Skeletal Tumor Burden on Baseline 18F-Fluoride PET/CT in Predicting Overall Survival.
Etchebehere EC; Araujo JC; Fox PS; Swanston NM; Macapinlac HA; Rohren EM
J Nucl Med; 2015 Aug; 56(8):1177-84. PubMed ID: 26069307
[TBL] [Abstract][Full Text] [Related]
15. Castration-resistant prostate cancer bone metastasis response measured by 18F-fluoride PET after treatment with dasatinib and correlation with progression-free survival: results from American College of Radiology Imaging Network 6687.
Yu EY; Duan F; Muzi M; Deng X; Chin BB; Alumkal JJ; Taplin ME; Taub JM; Herman B; Higano CS; Doot RK; Hartfeil D; Febbo PG; Mankoff DA
J Nucl Med; 2015 Mar; 56(3):354-60. PubMed ID: 25635138
[TBL] [Abstract][Full Text] [Related]
16. Prospective evaluation of [
Schwarzenböck SM; Eiber M; Kundt G; Retz M; Sakretz M; Kurth J; Treiber U; Nawroth R; Rummeny EJ; Gschwend JE; Schwaiger M; Thalgott M; Krause BJ
Eur J Nucl Med Mol Imaging; 2016 Nov; 43(12):2105-2113. PubMed ID: 27317482
[TBL] [Abstract][Full Text] [Related]
17. The potential of
Murray I; Chittenden SJ; Denis-Bacelar AM; Hindorf C; Parker CC; Chua S; Flux GD
Eur J Nucl Med Mol Imaging; 2017 Oct; 44(11):1832-1844. PubMed ID: 28612079
[TBL] [Abstract][Full Text] [Related]
18. Quantification of bone flare on
Weisman AJ; Harmon SA; Perk TG; Eickhoff J; Choyke PL; Kurdziel KA; Dahut WL; Humm JL; Apolo AB; Larson SM; Morris MJ; Perlman SB; Liu G; Jeraj R
Prostate Cancer Prostatic Dis; 2019 May; 22(2):324-330. PubMed ID: 30413807
[TBL] [Abstract][Full Text] [Related]
19. Observer Agreement and Accuracy of
Zacho HD; Fonager RF; Nielsen JB; Haarmark C; Hendel HW; Johansen MB; Mortensen JC; Petersen LJ
J Nucl Med; 2020 Mar; 61(3):344-349. PubMed ID: 31481577
[TBL] [Abstract][Full Text] [Related]
20. NaF PET/CT for response assessment of prostate cancer bone metastases treated with single fraction stereotactic ablative body radiotherapy.
Hardcastle N; Hofman MS; Lee CY; Callahan J; Selbie L; Foroudi F; Shaw M; Chander S; Lim A; Chesson B; Murphy DG; Kron T; Siva S
Radiat Oncol; 2019 Sep; 14(1):164. PubMed ID: 31488175
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]